Company Insights

ARTV supplier relationships

Explore interactive graphBrowse insights index
ARTV supplier relationship map

Artiva Biotherapeutics: supplier relationships that underpin an NK‑cell play

Artiva develops off‑the‑shelf NK cell therapies and monetizes through licensed technology, milestone and royalty payments, and—eventually—product sales and sublicensing. The company depends on a concentrated supplier ecosystem anchored by GC Cell (technology licensor and manufacturer) and a small number of clinical partners executing investigator‑initiated trials, creating both leverage for rapid development and single‑point operational risk. For primary sourcing and commercialization intelligence, review the supplier map at https://nullexposure.com/.

Why suppliers matter to an investor in ARTV

Artiva’s value hinges on converting preclinical and early clinical activity into scalable manufacturing and commercial supply. Key commercial levers are the exclusive license from GC Cell, a manufacturing master agreement, milestone obligations and the ability to scale NK production globally outside Asia/Australia/New Zealand. These are not abstract arrangements—contract language creates explicit economic and delivery dependencies that will influence capital needs, dilution risk and time to revenue.

For a concise supplier risk baseline, see https://nullexposure.com/ — the platform that aggregates these supplier signals and filings.

Operating model signals investors should read as a whole

  • Contract posture and maturity: Artiva holds a multi‑tiered licensing and manufacturing framework with GC Cell that dates to 2019 (Core Agreement) and a 2020 Master Agreement for Manufacturing Services; this is a developed, multi‑document contractual relationship rather than an ad hoc supplier tie. The company discloses exclusive licensing terms that permit sublicensing within defined territories, reflecting a deliberate commercialization architecture (company‑level signal supported by contract excerpts naming GC Cell).
  • Concentration and criticality: Several constraints identify GC Cell as both licensor and manufacturer, which makes that relationship strategically critical and materially important to clinical progress and eventual commercial supply. The company warns that loss of supplier continuity could materially impair trials or product launches (company‑level reading of disclosed risk language).
  • Financial commitments: Agreemented milestones tied to GC Cell total material sums (examples: up to $22.0M in development milestones and up to $55.0M in sales milestones), placing the relationship in a $10M–$100M spend band and linking commercial upside to contingent outflows.
  • Service ecosystem: Artiva also engages third‑party research and consulting providers for clinical operations and patient advocacy, signaling a hybrid model that mixes licensed manufacturing with outsourced clinical services.
  • Implication: High technical dependency + meaningful contingent spend = structurally elevated supplier risk, but also concentrated optionality: if AlloNK succeeds, the same structure provides a clear path to scale.

Explore supplier-level details and contracts at https://nullexposure.com/ for investor due diligence.

Detailed supplier relationships (each entry from the source material)

  • Integral Rheumatology & Immunology Specialists (IRIS) — In April 2024 the FDA cleared an IND submitted by IRIS, a community rheumatology practice in Florida, to run a basket investigator‑initiated trial assessing AlloNK plus rituximab in autoimmune indications including RA, PV, ANCA‑associated vasculitides and SLE. — Artiva Form 10‑K (filed FY2024).
  • GC Cell — Artiva was founded in 2019 as a spin‑out from GC Cell and holds exclusive worldwide rights (excluding Asia, Australia and New Zealand) to GC Cell’s NK cell manufacturing technology and programs under a strategic partnership described in a GlobeNewswire release announcing a board appointment (Feb 19, 2026). — GlobeNewswire press release, Feb 19, 2026.
  • GC Cell (formerly GC Lab Cell Corporation) — The company reiterated this origin and exclusive rights in its Q2 2025 financial and corporate update, noting GC Cell’s role in the underlying technology Artiva commercializes. — Artiva press release, Aug 6, 2025.
  • GC Cell — The same foundational licensing and manufacturing relationship with GC Cell is restated in a GlobeNewswire announcement tied to leadership changes and the company’s corporate narrative (Feb 24, 2026). — GlobeNewswire press release, Feb 24, 2026.
  • GC Cell — Multiple media placements repeating Artiva’s spin‑out origin and license arrangement appeared across global outlets as Artiva positioned AlloNK as a lead program (e.g., Manila Times coverage, Oct 17, 2025). — Manila Times / GlobeNewswire placement, Oct 17, 2025.
  • GC Cell — The Oct 16, 2025 GlobeNewswire release announcing refractory rheumatoid arthritis as the lead indication repeats the exclusive‑rights language and GC Cell pedigree. — GlobeNewswire press release, Oct 16, 2025.
  • GC Cell — In its Q3 2025 results, Artiva again referenced the licensing/manufacturing relationship with GC Cell as foundational to its pipeline and production strategy. — Artiva Q3 2025 financial results press release, Nov 12, 2025.
  • GC Cell — A GlobeNewswire release on Feb 19, 2026 (board appointment) reiterated GC Cell’s role in Artiva’s exclusive manufacturing and technology rights outside Asia/Australia/New Zealand. — GlobeNewswire press release, Feb 19, 2026.
  • GC Cell — A StockTitan news item reporting positive initial safety data reiterated Artiva’s roots as a GC Cell spin‑out and the tied technology access. — StockTitan news summary, 2025.
  • GC Cell (formerly GC Lab Cell Corporation) — Artiva’s participation at investor and scientific conferences (e.g., TD Cowen health‑care conference) has repeatedly included reference to the GC Cell licensing and manufacturing foundation. — GlobeNewswire conference announcement, Feb 25, 2026.
  • GC Cell — Repeat GlobeNewswire investor‑facing notices in early 2026 again cite the exclusive license and manufacturing relationship as the core supplier arrangement. — GlobeNewswire press release, Feb 25, 2026.
  • GC Cell — Market and PR channels (Yahoo Finance SG) reissued Artiva’s Feb 2026 governance announcement with the same GC Cell background statement. — Yahoo Finance SG, Feb 2026.
  • GC Cell (formerly GC Lab Cell Corporation) — The Globe and Mail press release syndication of the Feb 2026 board appointment referenced the GC Cell spin‑out origin and license. — The Globe and Mail press release syndication, Feb 2026.
  • GC Cell (formerly GC Lab Cell Corporation) — Syndicated and third‑party outlets (Quiver Quant, Oct–Nov 2025) repeated the core license/manufacturing story as Artiva prioritized AlloNK for autoimmune development. — Quiver Quant / press syndication, FY2025.
  • GC Cell — A March 24, 2025 full‑year results release formalized the GC Cell origin and license in the company’s investor narrative. — Artiva FY2024 results press release, Mar 24, 2025.
  • GC Cell — SahmCapital and other investor newsletters in Jan 2026 highlighted conference presentations and reiterated the GC Cell licensing/manufacturing relationship when discussing cost‑effectiveness data for AlloNK. — SahmCapital investor note, Jan 21, 2026.
  • GC Cell (formerly GC Lab Cell Corporation) — The Oct 16, 2025 corporate update reiterating RA as lead indication again tied the program to GC Cell’s licensed technology. — GlobeNewswire press release, Oct 16, 2025 (syndicated).
  • GC Cell — A number of syndicated releases in late 2025 covering positive initial safety and translational data cited the GC Cell origin language in corporate communications. — GlobeNewswire, Nov 12, 2025.
  • GC Cell (formerly GC Lab Cell Corporation) — Multiple press releases in early 2026 referencing upcoming presentations at scientific meetings included the same license/manufacturing attribution to GC Cell. — GlobeNewswire / conference announcements, Jan–Feb 2026.
  • GC Cell — A GlobeNewswire release summarizing the company’s participation in TD Cowen reiterated the spin‑out/ license origin language for investor audiences. — GlobeNewswire press release, Feb 25, 2026.
  • GC Cell — International press outlets (e.g., Yahoo, The Globe and Mail) republished Artiva’s Feb 2026 governance news with the GC Cell background statement intact. — International press syndication, Feb 2026.

Investment implications and concentrated risk

  • Positive operational leverage: The exclusive license + manufacturing master agreement with GC Cell gives Artiva a clean path to clinical supply and commercialization outside the carved‑out territories, and the company’s messaging consistently ties value creation to these arrangements.
  • Concentrated counterparty risk: Because GC Cell is both licensor and manufacturer, supplier disruption, quality failure or a contract dispute would affect both intellectual property and supply continuity—this is a single‑point failure mode investors must price.
  • Contingent cash commitments: Milestone payments up to ~$77M (development + sales milestones cited) align incentives but create future cash outflows contingent on success; given Artiva’s current zero revenue and negative EBITDA, milestone structure is a meaningful financing consideration.
  • Clinical partner diversification: Investigator‑initiated trials (for example the IRIS trial cleared in April 2024) provide external clinical validation channels and broaden execution pathways beyond company‑led trials.

For a focused supplier risk and contract summary tailored to investment models, visit https://nullexposure.com/ to see the full mapping of agreements and filings.

Bottom line

Artiva’s upside is tightly coupled with successful clinical proof points and uninterrupted manufacturing access via GC Cell. The contractual architecture provides a scalable path if clinical readouts are positive, but it also concentrates operational and financial risk in a small number of counterparties and contingent milestone obligations. Institutional ownership and analyst interest are supportive, but supplier diligence—document review of the Core Agreement and the Manufacturing Master Agreement—will determine how to weight upside versus dilution and operational risk.

Final due diligence starts with supplier documents and filings; review the mapped evidence and filings at https://nullexposure.com/ before forming an investment decision.